The University of Chicago Header Logo

Connection

Michael Charlton to Humans

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Humans.
Michael Charlton
Connection Strength
2.316
Humans
  1. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol. 2023 12; 79(6):1524-1541.
    View in: PubMed
    Score: 0.031
  2. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. BMC Gastroenterol. 2023 May 19; 23(1):160.
    View in: PubMed
    Score: 0.030
  3. Rational combination therapy for NASH: Insights from clinical trials and error. J Hepatol. 2023 05; 78(5):1073-1079.
    View in: PubMed
    Score: 0.030
  4. The Authors' Reply: Geographic Variation in the Utilization of HCV-viremic Donors Into HCV-negative Recipients. Transplantation. 2022 02 01; 106(2):e166.
    View in: PubMed
    Score: 0.028
  5. Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 10; 10(10):1198-1208.
    View in: PubMed
    Score: 0.027
  6. Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl. 2021 07; 27(7):1019-1031.
    View in: PubMed
    Score: 0.027
  7. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
    View in: PubMed
    Score: 0.026
  8. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020 Sep; 55(9):811-823.
    View in: PubMed
    Score: 0.025
  9. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology. 2020 07; 72(1):315-329.
    View in: PubMed
    Score: 0.025
  10. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol. 2020 Jul; 55(7):722-730.
    View in: PubMed
    Score: 0.025
  11. Nonalcoholic Steatohepatitis After Liver Transplantation. Liver Transpl. 2020 01; 26(1):141-159.
    View in: PubMed
    Score: 0.024
  12. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation. 2019 04; 103(4):733-746.
    View in: PubMed
    Score: 0.023
  13. Liver Allocation Policies in the USA: Past, Present, and the Future. Dig Dis Sci. 2019 04; 64(4):985-992.
    View in: PubMed
    Score: 0.023
  14. The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis. Hepatology. 2019 03; 69(3):931-933.
    View in: PubMed
    Score: 0.023
  15. Liver Transplantation for Nonalcoholic Steatohepatitis: New Evidence of a Profound Increase Across Age Cohorts. Transplantation. 2019 01; 103(1):1-2.
    View in: PubMed
    Score: 0.022
  16. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
    View in: PubMed
    Score: 0.021
  17. FGF-19 agonism for NASH: a short study of a long disease. Lancet. 2018 03 24; 391(10126):1124-1126.
    View in: PubMed
    Score: 0.021
  18. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clin Liver Dis. 2018 02; 22(1):201-211.
    View in: PubMed
    Score: 0.021
  19. Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
    View in: PubMed
    Score: 0.021
  20. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017 Jun 01; 312(6):G666-G680.
    View in: PubMed
    Score: 0.020
  21. Predictors of Cardiovascular Events After Liver Transplantation. Clin Liver Dis. 2017 05; 21(2):367-379.
    View in: PubMed
    Score: 0.020
  22. Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
    View in: PubMed
    Score: 0.020
  23. Roadmap for improving patient and graft survival in the next 10 years. Liver Transpl. 2016 11; 22(S1):71-78.
    View in: PubMed
    Score: 0.019
  24. Alcoholic Liver Disease and Liver Transplantation. Clin Liver Dis. 2016 08; 20(3):521-34.
    View in: PubMed
    Score: 0.019
  25. Nonalcoholic Fatty Liver Disease and Liver Transplantation. Clin Liver Dis. 2016 May; 20(2):403-17.
    View in: PubMed
    Score: 0.019
  26. Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med. 2016 04 28; 374(17):1688.
    View in: PubMed
    Score: 0.019
  27. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 07; 64(1):19-22.
    View in: PubMed
    Score: 0.019
  28. Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. Gastroenterology. 2016 06; 150(8):1849-62.
    View in: PubMed
    Score: 0.018
  29. Usefulness of Liver Transplantation in the Elderly: The Converging Impact of Risk and Benefit. Gastroenterology. 2016 Feb; 150(2):306-9.
    View in: PubMed
    Score: 0.018
  30. Response to Fibrosis progression in patients treated for hepatitis C recurrence. Liver Int. 2015 Dec; 35(12):2625.
    View in: PubMed
    Score: 0.018
  31. Genetic susceptibility to hepatitis E viral infection: An enigmatic virus gives up a secret. Hepatology. 2015 Nov; 62(5):1337-8.
    View in: PubMed
    Score: 0.018
  32. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016 Feb; 63(2):634-43.
    View in: PubMed
    Score: 0.018
  33. Lack of Survival Benefit Following Liver Transplantation With MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice. Gastroenterology. 2015 Sep; 149(3):531-4.
    View in: PubMed
    Score: 0.018
  34. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.018
  35. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.017
  36. Reply: To PMID 24824965. Hepatology. 2015 Apr; 61(4):1442-3.
    View in: PubMed
    Score: 0.017
  37. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol. 2015 Aug; 110(8):1126-33.
    View in: PubMed
    Score: 0.017
  38. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver Int. 2015 Jan; 35(1):9-11.
    View in: PubMed
    Score: 0.017
  39. Chronic kidney disease (CKD) and NAFLD: time for awareness and screening. J Hepatol. 2015 Apr; 62(4):983-4.
    View in: PubMed
    Score: 0.017
  40. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.017
  41. Improving long-term outcomes after liver transplantation. Clin Liver Dis. 2014 Aug; 18(3):717-30.
    View in: PubMed
    Score: 0.016
  42. Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology. 2014 Sep; 60(3):815-22.
    View in: PubMed
    Score: 0.016
  43. Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transpl. 2014 Jul; 20(7):791-7.
    View in: PubMed
    Score: 0.016
  44. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014 Jun; 14(6):1383-90.
    View in: PubMed
    Score: 0.016
  45. Decreased muscle mass in nonalcoholic fatty liver disease: new evidence of a link between growth hormone and fatty liver disease? Hepatology. 2014 May; 59(5):1668-70.
    View in: PubMed
    Score: 0.016
  46. Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
    View in: PubMed
    Score: 0.016
  47. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr; 60(4):691-8.
    View in: PubMed
    Score: 0.016
  48. How important is acute cellular rejection? Liver Transpl. 2013 Nov; 19 Suppl 2:S9-13.
    View in: PubMed
    Score: 0.016
  49. Victory and defeat at Heraclea - treating hepatitis C infection following liver transplantation with telaprevir and boceprevir. J Hepatol. 2014 Jan; 60(1):6-8.
    View in: PubMed
    Score: 0.016
  50. The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States. Am J Transplant. 2013 Nov; 13(11):2794-6.
    View in: PubMed
    Score: 0.016
  51. Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient. Liver Transpl. 2013 Aug; 19(8):787-9.
    View in: PubMed
    Score: 0.015
  52. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant. 2013 Sep; 13(9):2450-7.
    View in: PubMed
    Score: 0.015
  53. Preserving flow in liver transplant recipients: mTOR inhibitors everolimus and sirolimus are not peas from a pod. Am J Transplant. 2013 Jul; 13(7):1633-5.
    View in: PubMed
    Score: 0.015
  54. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013 Jun; 18(3):251-8.
    View in: PubMed
    Score: 0.015
  55. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity (Silver Spring). 2013 Sep; 21(9):1935-41.
    View in: PubMed
    Score: 0.015
  56. ChREBP in NASH - a liver transcription factor comes in from the cold. J Hepatol. 2013 Jul; 59(1):178-9.
    View in: PubMed
    Score: 0.015
  57. Interleukin-28B polymorphism in hepatitis C and liver transplantation. Liver Transpl. 2013 Jan; 19(1):49-58.
    View in: PubMed
    Score: 0.015
  58. Nutrition in alcoholic liver disease. Clin Liver Dis. 2012 Nov; 16(4):805-26.
    View in: PubMed
    Score: 0.015
  59. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest. 2012 Dec; 92(12):1712-25.
    View in: PubMed
    Score: 0.015
  60. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
    View in: PubMed
    Score: 0.014
  61. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012 Jul 27; 94(2):197-203.
    View in: PubMed
    Score: 0.014
  62. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul; 18(7):803-10.
    View in: PubMed
    Score: 0.014
  63. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar; 18(3):323-31.
    View in: PubMed
    Score: 0.014
  64. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant. 2012 Mar; 12(3):737-44.
    View in: PubMed
    Score: 0.014
  65. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012 Feb; 32(2):279-86.
    View in: PubMed
    Score: 0.013
  66. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011 Oct; 141(4):1249-53.
    View in: PubMed
    Score: 0.013
  67. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011 Jul; 54(1):3-5.
    View in: PubMed
    Score: 0.013
  68. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl. 2011 Jun; 17(6):723-32.
    View in: PubMed
    Score: 0.013
  69. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis. Obes Surg. 2011 Mar; 21(3):310-5.
    View in: PubMed
    Score: 0.013
  70. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011 Jan; 53(1):317-24.
    View in: PubMed
    Score: 0.013
  71. Posttransplant metabolic syndrome: new evidence of an epidemic and recommendations for management. Liver Transpl. 2011 Jan; 17(1):1-6.
    View in: PubMed
    Score: 0.013
  72. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl. 2011 Jan; 17(1):23-31.
    View in: PubMed
    Score: 0.013
  73. Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). Gastroenterology. 2011 Jan; 140(1):25-8.
    View in: PubMed
    Score: 0.013
  74. Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation. Liver Transpl. 2010 Aug; 16(8):990-8.
    View in: PubMed
    Score: 0.013
  75. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10(6):1420-7.
    View in: PubMed
    Score: 0.012
  76. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010 Jul; 53(1):199-206.
    View in: PubMed
    Score: 0.012
  77. Antibody-based immunosuppression following liver transplantation: the plot thickens. Am J Transplant. 2010 Mar; 10(3):445-6.
    View in: PubMed
    Score: 0.012
  78. Fetal obesity syndrome: maternal nutrition as a cause of nonalcoholic steatohepatitis. Hepatology. 2009 Dec; 50(6):1696-8.
    View in: PubMed
    Score: 0.012
  79. Fatty liver and liver transplantation. Clin Liver Dis. 2009 Nov; 13(4):621-30.
    View in: PubMed
    Score: 0.012
  80. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 2009 Nov; 15 Suppl 2:S83-9.
    View in: PubMed
    Score: 0.012
  81. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009 Nov; 15(11):S1-34.
    View in: PubMed
    Score: 0.012
  82. Medical hurricane: health care reform and hepatology. Hepatology. 2009 Nov; 50(5):1339-40.
    View in: PubMed
    Score: 0.012
  83. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9(8):1707-13.
    View in: PubMed
    Score: 0.012
  84. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13.
    View in: PubMed
    Score: 0.011
  85. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology. 2009 Apr; 49(4):1375-84.
    View in: PubMed
    Score: 0.011
  86. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33.
    View in: PubMed
    Score: 0.011
  87. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? Hepatology. 2008 May; 47(5):1431-3.
    View in: PubMed
    Score: 0.011
  88. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008 Mar; 8(3):667-72.
    View in: PubMed
    Score: 0.011
  89. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008 Feb; 47(2):484-92.
    View in: PubMed
    Score: 0.011
  90. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep. 2007 Mar; 9(1):23-30.
    View in: PubMed
    Score: 0.010
  91. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol. 2007 Feb; 102(2):409-11.
    View in: PubMed
    Score: 0.010
  92. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
    View in: PubMed
    Score: 0.009
  93. Hepatocyte tails. Clin Gastroenterol Hepatol. 2006 May; 4(5):564-5.
    View in: PubMed
    Score: 0.009
  94. Perioperative viral kinetics: new insights or the Emperor's new clothes? Liver Transpl. 2006 Feb; 12(2):194-5.
    View in: PubMed
    Score: 0.009
  95. Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis? Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):72-3.
    View in: PubMed
    Score: 0.009
  96. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr. 2006 01; 136(1 Suppl):295S-8S.
    View in: PubMed
    Score: 0.009
  97. Recurrence of hepatitis C infection: Where are we now? Liver Transpl. 2005 Nov; (11 Suppl 2):S57-62.
    View in: PubMed
    Score: 0.009
  98. Retransplantation for HCV--the view through a broken crystal ball. Liver Transpl. 2005 Apr; 11(4):382-3.
    View in: PubMed
    Score: 0.009
  99. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004 Dec; 2(12):1048-58.
    View in: PubMed
    Score: 0.008
  100. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004 Sep; 10(9):1120-30.
    View in: PubMed
    Score: 0.008
  101. Obesity in potential living donors: success with simplicity. Liver Transpl. 2004 Jun; 10(6):726-7.
    View in: PubMed
    Score: 0.008
  102. Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 2024 Feb 08; 9(3).
    View in: PubMed
    Score: 0.008
  103. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
    View in: PubMed
    Score: 0.008
  104. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis. 2004; 24 Suppl 2:79-88.
    View in: PubMed
    Score: 0.008
  105. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003 Nov; 9(11):S58-62.
    View in: PubMed
    Score: 0.008
  106. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023 Nov; 8(11):2033-2049.
    View in: PubMed
    Score: 0.008
  107. Management of recurrence of hepatitis C infection following liver transplantation. Minerva Chir. 2003 Oct; 58(5):717-24.
    View in: PubMed
    Score: 0.008
  108. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.008
  109. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003 Aug; 7(3):585-602.
    View in: PubMed
    Score: 0.008
  110. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant. 2003 Jul; 3(7):885-90.
    View in: PubMed
    Score: 0.008
  111. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology. 2003 Jul; 38(1):244-51.
    View in: PubMed
    Score: 0.008
  112. Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives. Gastroenterology. 2003 Jun; 124(7):1980-2.
    View in: PubMed
    Score: 0.008
  113. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023 10 01; 78(4):1223-1239.
    View in: PubMed
    Score: 0.008
  114. The impact of advancing donor age on histologic recurrence of hepatitis C infection: the perils of ignored maternal advice. Liver Transpl. 2003 May; 9(5):535-7.
    View in: PubMed
    Score: 0.008
  115. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 07; 21(8):2150-2166.
    View in: PubMed
    Score: 0.008
  116. SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal Inoculum. Viruses. 2023 03 14; 15(3).
    View in: PubMed
    Score: 0.007
  117. Pre-emptive treatment of recurrent hepatitis C infection. Liver Transpl. 2002 Oct; 8(10 Suppl 1):S50-4.
    View in: PubMed
    Score: 0.007
  118. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl. 2002 Sep; 8(9):814-21.
    View in: PubMed
    Score: 0.007
  119. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
    View in: PubMed
    Score: 0.007
  120. Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States. Transplantation. 2022 10 01; 106(10):2006-2018.
    View in: PubMed
    Score: 0.007
  121. Preservation solutions for static cold storage in donation after circulatory death and donation after brain death liver transplantation in the United States. Liver Transpl. 2022 09; 28(9):1454-1462.
    View in: PubMed
    Score: 0.007
  122. Patient and graft survival following liver transplantation for hepatitis C: much ado about something. Gastroenterology. 2002 Apr; 122(4):1162-5.
    View in: PubMed
    Score: 0.007
  123. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002 Apr; 35(4):898-904.
    View in: PubMed
    Score: 0.007
  124. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
    View in: PubMed
    Score: 0.007
  125. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002 Apr; 8(4):362-9.
    View in: PubMed
    Score: 0.007
  126. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open. 2022 03 30; 12(3):e056159.
    View in: PubMed
    Score: 0.007
  127. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022 05; 76(5):1030-1041.
    View in: PubMed
    Score: 0.007
  128. Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transpl. 2002 Jan; 8(1):47-9.
    View in: PubMed
    Score: 0.007
  129. Hepatitis C infection in liver transplantation. Am J Transplant. 2001 Sep; 1(3):197-203.
    View in: PubMed
    Score: 0.007
  130. Mandatory Hepatology Education for Internal Medicine Residents: Long-Term Effects and Implications for Workforce Needs. Hepatol Commun. 2021 11; 5(11):1953-1963.
    View in: PubMed
    Score: 0.007
  131. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001 Jul; 7(7):608-14.
    View in: PubMed
    Score: 0.007
  132. Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. Semin Liver Dis. 2021 08; 41(3):225-234.
    View in: PubMed
    Score: 0.007
  133. Simultaneous Heart-Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable Outcomes. Hepatology. 2021 04; 73(4):1464-1477.
    View in: PubMed
    Score: 0.007
  134. The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. Am J Transplant. 2021 04; 21(4):1365-1375.
    View in: PubMed
    Score: 0.006
  135. Impact of nutritional status on outcomes after liver transplantation. Transplantation. 2000 Nov 15; 70(9):1347-52.
    View in: PubMed
    Score: 0.006
  136. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000 Nov; 32(5):1125-30.
    View in: PubMed
    Score: 0.006
  137. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl. 2000 Sep; 6(5):575-81.
    View in: PubMed
    Score: 0.006
  138. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant. 2021 03; 21(3):1039-1055.
    View in: PubMed
    Score: 0.006
  139. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation. 2000 Jul 27; 70(2):292-7.
    View in: PubMed
    Score: 0.006
  140. Hiding in the Water. N Engl J Med. 2020 May 07; 382(19):1844-1849.
    View in: PubMed
    Score: 0.006
  141. Genotype 1b and severity of posttransplant recurrence of hepatitis C infection- unconvictable felon or wrongly accused? Liver Transpl. 2000 Mar; 6(2):243-5.
    View in: PubMed
    Score: 0.006
  142. The effect of insulin on human small intestinal mucosal protein synthesis. Gastroenterology. 2000 Feb; 118(2):299-306.
    View in: PubMed
    Score: 0.006
  143. Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings. J Viral Hepat. 2020 05; 27(5):466-475.
    View in: PubMed
    Score: 0.006
  144. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.
    View in: PubMed
    Score: 0.006
  145. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S107-14.
    View in: PubMed
    Score: 0.006
  146. Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. J Heart Lung Transplant. 2019 09; 38(9):997-999.
    View in: PubMed
    Score: 0.006
  147. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology. 2019 06; 69(6):2381-2395.
    View in: PubMed
    Score: 0.006
  148. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
    View in: PubMed
    Score: 0.006
  149. Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Diabetes. 1998 Nov; 47(11):1748-56.
    View in: PubMed
    Score: 0.006
  150. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
    View in: PubMed
    Score: 0.006
  151. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998 Sep; 28(3):823-30.
    View in: PubMed
    Score: 0.005
  152. TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology. 1998 Sep; 28(3):839-42.
    View in: PubMed
    Score: 0.005
  153. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018 11; 155(5):1463-1473.e6.
    View in: PubMed
    Score: 0.005
  154. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371.
    View in: PubMed
    Score: 0.005
  155. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018 07; 68(1):349-360.
    View in: PubMed
    Score: 0.005
  156. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis. J Hepatol. 2018 09; 69(3):617-625.
    View in: PubMed
    Score: 0.005
  157. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol. 2018 Mar 28; 24(12):1321-1331.
    View in: PubMed
    Score: 0.005
  158. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
    View in: PubMed
    Score: 0.005
  159. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 10; 38(10):1849-1859.
    View in: PubMed
    Score: 0.005
  160. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr. 1998 02; 128(2 Suppl):323S-327S.
    View in: PubMed
    Score: 0.005
  161. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. JCI Insight. 2018 01 25; 3(2).
    View in: PubMed
    Score: 0.005
  162. Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring? Transplantation. 1998 Jan 15; 65(1):73-6.
    View in: PubMed
    Score: 0.005
  163. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559.
    View in: PubMed
    Score: 0.005
  164. Modeling the target dose fall-off in IMRT and VMAT planning techniques for cervical SBRT. Med Dosim. 2018 Spring; 43(1):1-10.
    View in: PubMed
    Score: 0.005
  165. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 01; 67(1):328-357.
    View in: PubMed
    Score: 0.005
  166. Skeletal muscle myosin heavy chain synthesis in type 1 diabetes. Diabetes. 1997 Aug; 46(8):1336-40.
    View in: PubMed
    Score: 0.005
  167. Liver transplantation for cryptogenic cirrhosis. Liver Transpl Surg. 1997 Jul; 3(4):359-64.
    View in: PubMed
    Score: 0.005
  168. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017 Nov; 17(11):2790-2802.
    View in: PubMed
    Score: 0.005
  169. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
    View in: PubMed
    Score: 0.005
  170. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
    View in: PubMed
    Score: 0.005
  171. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.005
  172. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
    View in: PubMed
    Score: 0.005
  173. Protein metabolism and liver disease. Baillieres Clin Endocrinol Metab. 1996 Oct; 10(4):617-35.
    View in: PubMed
    Score: 0.005
  174. Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah. Dig Dis Sci. 2016 12; 61(12):3627-3632.
    View in: PubMed
    Score: 0.005
  175. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
    View in: PubMed
    Score: 0.005
  176. Evidence for a catabolic role of glucagon during an amino acid load. J Clin Invest. 1996 Jul 01; 98(1):90-9.
    View in: PubMed
    Score: 0.005
  177. Branched chains revisited. Gastroenterology. 1996 Jul; 111(1):252-5.
    View in: PubMed
    Score: 0.005
  178. Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. Gastroenterology. 2016 10; 151(4):633-636.e3.
    View in: PubMed
    Score: 0.005
  179. Protecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant. 2016 09; 16(9):2516-31.
    View in: PubMed
    Score: 0.005
  180. Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. J Hepatol. 2016 08; 65(2):334-43.
    View in: PubMed
    Score: 0.005
  181. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.005
  182. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterology. 2016 Apr; 150(4):956-67.
    View in: PubMed
    Score: 0.005
  183. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
    View in: PubMed
    Score: 0.005
  184. Obesity is independently associated with infection in hospitalised patients with end-stage liver disease. Aliment Pharmacol Ther. 2015 Dec; 42(11-12):1271-80.
    View in: PubMed
    Score: 0.004
  185. Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infect Dis. 2015 Sep 02; 15:371.
    View in: PubMed
    Score: 0.004
  186. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015 May; 21(5):599-606.
    View in: PubMed
    Score: 0.004
  187. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015 May; 61(5):1485-94.
    View in: PubMed
    Score: 0.004
  188. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015 Feb; 21(2):248-57.
    View in: PubMed
    Score: 0.004
  189. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014 Sep 17; 6(254):254ra129.
    View in: PubMed
    Score: 0.004
  190. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014 Jul; 11(7):e1001680.
    View in: PubMed
    Score: 0.004
  191. A randomized, prospective, parallel group study of laparoscopic versus laparoendoscopic single site donor nephrectomy for kidney donation. Am J Transplant. 2014 Jul; 14(7):1630-7.
    View in: PubMed
    Score: 0.004
  192. Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc. 2014 May; 89(5):595-601.
    View in: PubMed
    Score: 0.004
  193. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int. 2014 Sep; 34(8):1259-66.
    View in: PubMed
    Score: 0.004
  194. Early MRI in term infants with perinatal hypoxic-ischaemic brain injury: interobserver agreement and MRI predictors of outcome at 2 years. Clin Radiol. 2014 Jan; 69(1):72-81.
    View in: PubMed
    Score: 0.004
  195. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013 Aug; 19(8):887-95.
    View in: PubMed
    Score: 0.004
  196. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013 Aug; 26(8):788-94.
    View in: PubMed
    Score: 0.004
  197. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
    View in: PubMed
    Score: 0.004
  198. Hepatic artery pseudoaneurysm formation following intraductal biliary radiofrequency ablation. Endoscopy. 2013; 45 Suppl 2 UCTN:E161-2.
    View in: PubMed
    Score: 0.004
  199. Measurement and analysis of 8-hour time-weighted average sound pressure levels in a vivarium decontamination facility. Arch Environ Occup Health. 2013; 68(3):173-9.
    View in: PubMed
    Score: 0.004
  200. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013 Feb; 13(2):363-8.
    View in: PubMed
    Score: 0.004
  201. Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. Eur Respir Rev. 2012 Sep 01; 21(125):223-33.
    View in: PubMed
    Score: 0.004
  202. Introduction to the genetics and biology of interleukin-28B. Hepatology. 2012 Jul; 56(1):361-6.
    View in: PubMed
    Score: 0.004
  203. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun; 55(6):2005-23.
    View in: PubMed
    Score: 0.004
  204. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012 Jun; 107(6):811-26.
    View in: PubMed
    Score: 0.004
  205. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012 Jun; 142(7):1592-609.
    View in: PubMed
    Score: 0.004
  206. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr; 56(4):1838-44.
    View in: PubMed
    Score: 0.003
  207. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci. 2012 Apr; 57(4):952-7.
    View in: PubMed
    Score: 0.003
  208. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.003
  209. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg. 2011 Nov; 21(11):1714-20.
    View in: PubMed
    Score: 0.003
  210. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011 Sep 02; 54(3):1063-70.
    View in: PubMed
    Score: 0.003
  211. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res. 2011 Aug; 52(8):1517-25.
    View in: PubMed
    Score: 0.003
  212. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
    View in: PubMed
    Score: 0.003
  213. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010 Dec; 20(12):1698-709.
    View in: PubMed
    Score: 0.003
  214. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44(8):e178-85.
    View in: PubMed
    Score: 0.003
  215. Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther. 2010 Sep; 32(6):776-86.
    View in: PubMed
    Score: 0.003
  216. Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis. Hepatology. 2010 Jul; 52(1):238-48.
    View in: PubMed
    Score: 0.003
  217. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest. 2010 Jul; 120(7):2379-94.
    View in: PubMed
    Score: 0.003
  218. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010 Apr; 52(4):586-93.
    View in: PubMed
    Score: 0.003
  219. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem. 2009 Sep 25; 284(39):26591-602.
    View in: PubMed
    Score: 0.003
  220. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009 Jul 27; 88(2):219-25.
    View in: PubMed
    Score: 0.003
  221. Asynchronous, out-of-sequence, transcontinental chain kidney transplantation: a novel concept. Am J Transplant. 2009 Sep; 9(9):2180-5.
    View in: PubMed
    Score: 0.003
  222. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol. 2007 Dec; 157(6):1183-8.
    View in: PubMed
    Score: 0.003
  223. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
    View in: PubMed
    Score: 0.003
  224. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27; 83(12):1639-42.
    View in: PubMed
    Score: 0.003
  225. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007 Mar; 5(3):394-402; quiz 267.
    View in: PubMed
    Score: 0.002
  226. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006 Sep; 12(9):1381-9.
    View in: PubMed
    Score: 0.002
  227. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2005 Oct; 11(10):1207-13.
    View in: PubMed
    Score: 0.002
  228. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol. 2005 Apr; 100(4):874-8.
    View in: PubMed
    Score: 0.002
  229. Hypophosphatemia after right hepatectomy for living donor liver transplantation. Can J Gastroenterol. 2004 Dec; 18(12):729-33.
    View in: PubMed
    Score: 0.002
  230. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant. 2003 Jun; 3(6):743-53.
    View in: PubMed
    Score: 0.002
  231. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002 Oct 15; 35(8):974-81.
    View in: PubMed
    Score: 0.002
  232. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol. 2002 Jun; 167(6):2408-12.
    View in: PubMed
    Score: 0.002
  233. Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol. 2002 Jun; 97(6):1472-5.
    View in: PubMed
    Score: 0.002
  234. Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis. Hum Pathol. 2002 Apr; 33(4):435-6.
    View in: PubMed
    Score: 0.002
  235. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 2001 Apr; 7(4):302-10.
    View in: PubMed
    Score: 0.002
  236. Prevalence of TT virus infection in blood donors with elevated ALT in the absence of known hepatitis markers. Am J Gastroenterol. 2000 Mar; 95(3):772-6.
    View in: PubMed
    Score: 0.002
  237. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol. 2000 Mar; 13(3):229-37.
    View in: PubMed
    Score: 0.002
  238. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000 Feb; 163(2):524-7.
    View in: PubMed
    Score: 0.002
  239. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999 Nov; 30(5):1121-7.
    View in: PubMed
    Score: 0.001
  240. Clinical significance of TT virus infection in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Oct; 94(10):3020-7.
    View in: PubMed
    Score: 0.001
  241. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999 Apr; 29(4):1050-6.
    View in: PubMed
    Score: 0.001
  242. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999 Apr; 29(4):1220-6.
    View in: PubMed
    Score: 0.001
  243. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Apr; 94(4):1000-5.
    View in: PubMed
    Score: 0.001
  244. Hepatotoxicity after desflurane anesthesia. Anesthesiology. 1995 Nov; 83(5):1125-9.
    View in: PubMed
    Score: 0.001
  245. Cancer in young people in the north of England, 1968-85: analysis by census wards. J Epidemiol Community Health. 1993 Apr; 47(2):109-15.
    View in: PubMed
    Score: 0.001
  246. Endoscopic therapy for bile duct stones in a geriatric population. Postgrad Med J. 1992 Jun; 68(800):457-60.
    View in: PubMed
    Score: 0.001
  247. Factors influencing mortality and morbidity following oesophageal resection. Eur J Cardiothorac Surg. 1989; 3(5):419-23; discussion 424.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.